Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna Posted on 3rd March 20253rd March 2025
Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics Posted on 21st October 202422nd October 2024
Repair Biotechnologies and Genevant Sciences to Collaborate to Develop mRNA-LNP Therapy with First-in-Class Potential to Turn Back Atherosclerosis Posted on 26th September 2024
Genevant Sciences to Collaborate with Tome Biosciences to Develop Gene Editing Therapeutic for Rare Liver Disorder Posted on 16th January 202416th January 2024
Genevant Sciences to Collaborate with Novo Nordisk to Develop Gene Editing Treatment for Hemophilia A Posted on 6th November 2023
Genevant Sciences LNP Technology Used in samRNA Covid-19 Vaccine Candidate Behind Gritstone bio’s BARDA Award Posted on 12th October 202312th October 2023
Gritstone bio and Genevant Sciences Announce Option and License Agreement Posted on 15th August 202315th August 2023
Korro Bio and Genevant Sciences Enter into Collaboration Agreement to Develop RNA Editing Therapeutic for Alpha-1 Antitrypsin Deficiency Posted on 7th March 2023
Genevant Sciences and Arbutus Biopharma File Patent Infringement Lawsuit Against Moderna Posted on 28th February 2022
